Is molnupiravir capsules available in pharmacies?

Molnupiravir capsules (Molnupiravir) is a new drug used to treat COVID-19 with many potentially important features. The mechanism of action of monogravir capsules is very unique. This drug is a nucleoside analog, which can simulate the nucleotides required for viral RNA replication and interfere with the viral replication process. When patients take monogravir capsules orally, the drug enters the body, is absorbed and metabolized into active metabolites. These metabolites can be embedded into viral RNA chains and prevent viral replication, thereby reducing viral load and mitigating the symptoms and spread of COVID-19.

Monolavir capsules are already on the market in China, but are not yet included in medical insurance. Please consult your local hospital pharmacy for specific prices. The cheaper ones abroad are Indian generic drugs, which cost around three to four hundred yuan, and the ingredients of domestic original drugs and foreign generic drugs are basically the same.

Monoravir capsules are indicated for the treatment of adult patients with confirmed infectionCOVID-19, particularly in the early stages of infection. The standard treatment plan is to take 800 mg orally twice a day for 5 consecutive days. The goal of this treatment program is to intervene early, reduce the risk of hospitalization and death, and alleviate symptoms.

A number of side effects have been observed in clinical trials and studies of monogravir capsules, including nausea, vomiting, diarrhea, headache, fatigue, abnormal liver function, heart-related problems, and allergic reactions. However, most side effects are short-term and usually mild. Patients should pay close attention to any discomfort while using monogravir capsules and report it to their doctor promptly. Monolavir capsules represent a new approach to treating COVID-19, particularly in early cases of infection, and have the potential to reduce symptoms and risk of hospitalization while providing more treatment options.